ID   RFXK_HUMAN              Reviewed;         260 AA.
AC   O14593; O95839; Q24JQ1; Q6FGA8;
DT   15-JUL-1999, integrated into UniProtKB/Swiss-Prot.
DT   15-JUL-1999, sequence version 2.
DT   28-JAN-2026, entry version 216.
DE   RecName: Full=DNA-binding protein RFXANK;
DE   AltName: Full=Ankyrin repeat family A protein 1;
DE   AltName: Full=Regulatory factor X subunit B;
DE            Short=RFX-B;
DE   AltName: Full=Regulatory factor X-associated ankyrin-containing protein;
GN   Name=RFXANK; Synonyms=ANKRA1, RFXB;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), IDENTIFICATION BY MASS
RP   SPECTROMETRY, FUNCTION, AND INVOLVEMENT IN MHC2D2.
RC   TISSUE=B-cell;
RX   PubMed=9806546; DOI=10.1038/3081;
RA   Masternak K., Barras E., Zufferey M., Conrad B., Corthals G., Aebersold R.,
RA   Sanchez J.-C., Hochstrasser D.F., Mach B., Reith W.;
RT   "A gene encoding a novel RFX-associated transactivator is mutated in the
RT   majority of MHC class II deficiency patients.";
RL   Nat. Genet. 20:273-277(1998).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORMS 1 AND 2), PROTEIN SEQUENCE OF 79-95;
RP   180-198; 100-210 AND 238-248, FUNCTION (ISOFORMS 1 AND 2), AND INVOLVEMENT
RP   IN MHC2D2.
RC   TISSUE=Lymphoblast;
RX   PubMed=10072068; DOI=10.1016/s1074-7613(00)80016-3;
RA   Nagarajan U.M., Louis-Plence P., DeSandro A., Nilsen R., Bushey A.,
RA   Boss J.M.;
RT   "RFX-B is the gene responsible for the most common cause of the bare
RT   lymphocyte syndrome, an MHC class II immunodeficiency.";
RL   Immunity 10:153-162(1999).
RN   [3]
RP   ERRATUM OF PUBMED:10072068.
RA   Nagarajan U.M., Louis-Plence P., DeSandro A., Nilsen R., Bushey A.,
RA   Boss J.M.;
RL   Immunity 10:399-399(1999).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1).
RC   TISSUE=Umbilical cord blood;
RX   PubMed=11042152; DOI=10.1101/gr.140200;
RA   Zhang Q.-H., Ye M., Wu X.-Y., Ren S.-X., Zhao M., Zhao C.-J., Fu G.,
RA   Shen Y., Fan H.-Y., Lu G., Zhong M., Xu X.-R., Han Z.-G., Zhang J.-W.,
RA   Tao J., Huang Q.-H., Zhou J., Hu G.-X., Gu J., Chen S.-J., Chen Z.;
RT   "Cloning and functional analysis of cDNAs with open reading frames for 300
RT   previously undefined genes expressed in CD34+ hematopoietic stem/progenitor
RT   cells.";
RL   Genome Res. 10:1546-1560(2000).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1).
RA   Ebert L., Schick M., Neubert P., Schatten R., Henze S., Korn B.;
RT   "Cloning of human full open reading frames in Gateway(TM) system entry
RT   vector (pDONR201).";
RL   Submitted (JUN-2004) to the EMBL/GenBank/DDBJ databases.
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=15057824; DOI=10.1038/nature02399;
RA   Grimwood J., Gordon L.A., Olsen A.S., Terry A., Schmutz J., Lamerdin J.E.,
RA   Hellsten U., Goodstein D., Couronne O., Tran-Gyamfi M., Aerts A.,
RA   Altherr M., Ashworth L., Bajorek E., Black S., Branscomb E., Caenepeel S.,
RA   Carrano A.V., Caoile C., Chan Y.M., Christensen M., Cleland C.A.,
RA   Copeland A., Dalin E., Dehal P., Denys M., Detter J.C., Escobar J.,
RA   Flowers D., Fotopulos D., Garcia C., Georgescu A.M., Glavina T., Gomez M.,
RA   Gonzales E., Groza M., Hammon N., Hawkins T., Haydu L., Ho I., Huang W.,
RA   Israni S., Jett J., Kadner K., Kimball H., Kobayashi A., Larionov V.,
RA   Leem S.-H., Lopez F., Lou Y., Lowry S., Malfatti S., Martinez D.,
RA   McCready P.M., Medina C., Morgan J., Nelson K., Nolan M., Ovcharenko I.,
RA   Pitluck S., Pollard M., Popkie A.P., Predki P., Quan G., Ramirez L.,
RA   Rash S., Retterer J., Rodriguez A., Rogers S., Salamov A., Salazar A.,
RA   She X., Smith D., Slezak T., Solovyev V., Thayer N., Tice H., Tsai M.,
RA   Ustaszewska A., Vo N., Wagner M., Wheeler J., Wu K., Xie G., Yang J.,
RA   Dubchak I., Furey T.S., DeJong P., Dickson M., Gordon D., Eichler E.E.,
RA   Pennacchio L.A., Richardson P., Stubbs L., Rokhsar D.S., Myers R.M.,
RA   Rubin E.M., Lucas S.M.;
RT   "The DNA sequence and biology of human chromosome 19.";
RL   Nature 428:529-535(2004).
RN   [7]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L., Mobarry C.M.,
RA   Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J.,
RA   Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S.,
RA   Turner R., Yooseph S., Lu F., Nusskern D.R., Shue B.C., Zheng X.H.,
RA   Zhong F., Delcher A.L., Huson D.H., Kravitz S.A., Mouchard L., Reinert K.,
RA   Remington K.A., Clark A.G., Waterman M.S., Eichler E.E., Adams M.D.,
RA   Hunkapiller M.W., Myers E.W., Venter J.C.;
RL   Submitted (JUL-2005) to the EMBL/GenBank/DDBJ databases.
RN   [8]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORMS 1 AND 3).
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [9]
RP   SUBUNIT.
RX   PubMed=20732328; DOI=10.1016/j.jmb.2010.08.025;
RA   Laird K.M., Briggs L.L., Boss J.M., Summers M.F., Garvie C.W.;
RT   "Solution structure of the heterotrimeric complex between the interaction
RT   domains of RFX5 and RFXAP from the RFX gene regulatory complex.";
RL   J. Mol. Biol. 403:40-51(2010).
RN   [10]
RP   INTERACTION WITH RFX7.
RX   PubMed=25752541; DOI=10.1016/j.str.2015.02.001;
RA   Nie J., Xu C., Jin J., Aka J.A., Tempel W., Nguyen V., You L., Weist R.,
RA   Min J., Pawson T., Yang X.J.;
RT   "Ankyrin repeats of ANKRA2 recognize a PxLPxL motif on the 3M syndrome
RT   protein CCDC8.";
RL   Structure 23:700-712(2015).
RN   [11]
RP   X-RAY CRYSTALLOGRAPHY (1.57 ANGSTROMS) OF 90-260 IN COMPLEX WITH RFX5
RP   PEPTIDE, CHARACTERIZATION OF VARIANT MHC2D2 PRO-195, AND MUTAGENESIS OF
RP   ASP-121 AND TYR-224.
RX   PubMed=22649097; DOI=10.1126/scisignal.2002979;
RA   Xu C., Jin J., Bian C., Lam R., Tian R., Weist R., You L., Nie J.,
RA   Bochkarev A., Tempel W., Tan C.S., Wasney G.A., Vedadi M., Gish G.D.,
RA   Arrowsmith C.H., Pawson T., Yang X.J., Min J.;
RT   "Sequence-specific recognition of a PxLPxI/L motif by an ankyrin repeat
RT   tumbler lock.";
RL   Sci. Signal. 5:RA39-RA39(2012).
RN   [12]
RP   X-RAY CRYSTALLOGRAPHY (1.78 ANGSTROMS) OF 90-260 IN COMPLEX WITH RFX7.
RA   Tempel W., Xu C., Dong A., Li Y., Bountra C., Arrowsmith C.H.,
RA   Edwards A.M., Min J.;
RT   "Crystal structure of RFXANK ankyrin repeats in complex with RFX7.";
RL   Submitted (JUN-2014) to the PDB data bank.
RN   [13]
RP   VARIANT MHC2D2 PRO-195, FUNCTION, AND INVOLVEMENT IN MHC2D2.
RX   PubMed=10725724; DOI=10.4049/jimmunol.164.7.3666;
RA   Nagarajan U.M., Peijnenburg A., Gobin S.J., Boss J.M., van den Elsen P.J.;
RT   "Novel mutations within the RFX-B gene and partial rescue of MHC and
RT   related genes through exogenous class II transactivator in RFX-B-deficient
RT   cells.";
RL   J. Immunol. 164:3666-3674(2000).
RN   [14]
RP   VARIANT MHC2D2 PRO-144, AND INVOLVEMENT IN MHC2D2.
RX   PubMed=30170160; DOI=10.1016/j.jaip.2018.07.046;
RA   El Hawary R.E., Mauracher A.A., Meshaal S.S., Eldash A., Abd Elaziz D.S.,
RA   Alkady R., Lotfy S., Opitz L., Galal N.M., Boutros J.A.,
RA   Pachlopnik Schmid J., Elmarsafy A.M.;
RT   "MHC-II Deficiency Among Egyptians: Novel Mutations and Unique
RT   Phenotypes.";
RL   J. Allergy Clin. Immunol. Pract. 7:856-863(2019).
RN   [15]
RP   VARIANTS MHC2D2 HIS-121 AND 212-ARG--GLU-260 DEL, AND INVOLVEMENT IN
RP   MHC2D2.
RX   PubMed=37584719; DOI=10.1007/s10875-023-01562-z;
RA   Mousavi Khorshidi M.S., Seeleuthner Y., Chavoshzadeh Z., Behfar M.,
RA   Hamidieh A.A., Alimadadi H., Sherkat R., Momen T., Behniafard N.,
RA   Eskandarzadeh S., Mansouri M., Behnam M., Mahdavi M., Heydarazad Zadeh M.,
RA   Shokri M., Alizadeh F., Movahedi M., Momenilandi M., Keramatipour M.,
RA   Casanova J.L., Cobat A., Abel L., Shahrooei M., Parvaneh N.;
RT   "Clinical, Immunological, and Genetic Findings in Iranian Patients with
RT   MHC-II Deficiency: Confirmation of c.162delG RFXANK Founder Mutation in the
RT   Iranian Population.";
RL   J. Clin. Immunol. 43:1941-1952(2023).
CC   -!- FUNCTION: Activates transcription from class II MHC promoters.
CC       Activation requires the activity of the MHC class II
CC       transactivator/CIITA. May regulate other genes in the cell. RFX binds
CC       the X1 box of MHC-II promoters (PubMed:10072068, PubMed:10725724,
CC       PubMed:9806546). May also potentiate the activation of RAF1 (By
CC       similarity). {ECO:0000250|UniProtKB:Q9Z205,
CC       ECO:0000269|PubMed:10072068, ECO:0000269|PubMed:10725724,
CC       ECO:0000269|PubMed:9806546}.
CC   -!- FUNCTION: Isoform 2 is not involved in the positive regulation of MHC
CC       class II genes. {ECO:0000269|PubMed:10072068}.
CC   -!- SUBUNIT: Forms homodimers (By similarity). The RFX heterotetrameric
CC       complex consists of 2 molecules of RFX5 and one each of RFXAP and RFX-
CC       B/RFXANK; with each subunit representing a separate complementation
CC       group. Interacts (via ankyrin repeats) with RFX5 (via PxLPxI/L motif);
CC       the interaction is direct. RFX forms cooperative DNA binding complexes
CC       with X2BP and CBF/NF-Y. RFX associates with CIITA to form an active
CC       transcriptional complex (PubMed:20732328, PubMed:22649097). Interacts
CC       with RAF1 (By similarity). Interacts (via ankyrin repeats) with RFX7
CC       (via PxLPxI/L motif) (PubMed:25752541). {ECO:0000250|UniProtKB:Q9Z205,
CC       ECO:0000269|PubMed:20732328, ECO:0000269|PubMed:22649097,
CC       ECO:0000269|PubMed:25752541, ECO:0000312|PDB:6MEW}.
CC   -!- INTERACTION:
CC       O14593; P48382: RFX5; NbExp=12; IntAct=EBI-1057665, EBI-923266;
CC       O14593; Q2KHR2: RFX7; NbExp=6; IntAct=EBI-1057665, EBI-1222187;
CC       O14593; O00287: RFXAP; NbExp=7; IntAct=EBI-1057665, EBI-3929296;
CC   -!- SUBCELLULAR LOCATION: Cytoplasm {ECO:0000250|UniProtKB:Q9Z205}. Nucleus
CC       {ECO:0000250|UniProtKB:Q9Z205}.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=3;
CC       Name=1; Synonyms=Long;
CC         IsoId=O14593-1; Sequence=Displayed;
CC       Name=2; Synonyms=RFX-B-delta5;
CC         IsoId=O14593-2; Sequence=VSP_000283, VSP_000284, VSP_054618;
CC       Name=3;
CC         IsoId=O14593-3; Sequence=VSP_000284;
CC   -!- TISSUE SPECIFICITY: Ubiquitous.
CC   -!- DOMAIN: Interacts with RAF1 via its C-terminal ankyrin repeat domain.
CC       The same domain also mediates its homodimerization (By similarity). The
CC       third ankyrin repeat is required for association with the two other RFX
CC       subunits; RFX5 and RFXAP. The three central ANK repeats mediate binding
CC       to the PxLPxI/L motif of RFX5 (PubMed:20732328, PubMed:22649097).
CC       {ECO:0000250|UniProtKB:Q9Z205, ECO:0000269|PubMed:20732328,
CC       ECO:0000269|PubMed:22649097}.
CC   -!- PTM: Phosphorylated by RAF1. {ECO:0000250|UniProtKB:Q9Z205}.
CC   -!- DISEASE: MHC class II deficiency 2 (MHC2D2) [MIM:620815]: An autosomal
CC       recessive disorder characterized by immunodeficiency and recurrent
CC       bacterial, viral, fungal and parasitic infections in early infancy.
CC       Additional manifestations include failure to thrive, chronic diarrhea,
CC       and autoimmune features and allergies that may be present in some
CC       patients. Death often occurs in infancy or early childhood.
CC       {ECO:0000269|PubMed:10072068, ECO:0000269|PubMed:10725724,
CC       ECO:0000269|PubMed:22649097, ECO:0000269|PubMed:30170160,
CC       ECO:0000269|PubMed:37584719, ECO:0000269|PubMed:9806546}. Note=The
CC       disease is caused by variants affecting the gene represented in this
CC       entry.
CC   -!- WEB RESOURCE: Name=RFXANKbase; Note=RFXANK mutation db;
CC       URL="https://databases.lovd.nl/shared/genes/RFXANK";
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; AF094760; AAC69883.1; -; mRNA.
DR   EMBL; AF105427; AAD17972.1; -; mRNA.
DR   EMBL; AF105428; AAD17973.1; -; mRNA.
DR   EMBL; AF077196; AAD26991.1; -; mRNA.
DR   EMBL; CR542199; CAG46996.1; -; mRNA.
DR   EMBL; AC002126; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AC003110; AAB86654.1; -; Genomic_DNA.
DR   EMBL; CH471106; EAW84795.1; -; Genomic_DNA.
DR   EMBL; BC114558; AAI14559.1; -; mRNA.
DR   EMBL; BC114563; AAI14564.1; -; mRNA.
DR   CCDS; CCDS12395.1; -. [O14593-1]
DR   CCDS; CCDS62611.1; -. [O14593-3]
DR   RefSeq; NP_001265656.1; NM_001278727.2. [O14593-3]
DR   RefSeq; NP_001265657.1; NM_001278728.1.
DR   RefSeq; NP_001357162.1; NM_001370233.1. [O14593-1]
DR   RefSeq; NP_001357163.1; NM_001370234.1. [O14593-3]
DR   RefSeq; NP_003712.1; NM_003721.4. [O14593-1]
DR   RefSeq; NP_604389.1; NM_134440.2.
DR   RefSeq; XP_005260191.1; XM_005260134.6. [O14593-1]
DR   RefSeq; XP_054178453.1; XM_054322478.1. [O14593-1]
DR   PDB; 3UXG; X-ray; 1.85 A; A=90-260.
DR   PDB; 3V30; X-ray; 1.57 A; A=90-260.
DR   PDB; 6MEW; X-ray; 1.78 A; A/C=90-260.
DR   PDBsum; 3UXG; -.
DR   PDBsum; 3V30; -.
DR   PDBsum; 6MEW; -.
DR   AlphaFoldDB; O14593; -.
DR   SMR; O14593; -.
DR   BioGRID; 114180; 166.
DR   ComplexPortal; CPX-6461; RFX gene regulatory complex.
DR   CORUM; O14593; -.
DR   ELM; O14593; -.
DR   FunCoup; O14593; 1831.
DR   IntAct; O14593; 138.
DR   STRING; 9606.ENSP00000305071; -.
DR   iPTMnet; O14593; -.
DR   PhosphoSitePlus; O14593; -.
DR   BioMuta; RFXANK; -.
DR   jPOST; O14593; -.
DR   MassIVE; O14593; -.
DR   PaxDb; 9606-ENSP00000305071; -.
DR   PeptideAtlas; O14593; -.
DR   ProteomicsDB; 48101; -. [O14593-1]
DR   ProteomicsDB; 48102; -. [O14593-2]
DR   ProteomicsDB; 61266; -.
DR   Pumba; O14593; -.
DR   Antibodypedia; 15290; 361 antibodies from 21 providers.
DR   DNASU; 8625; -.
DR   Ensembl; ENST00000303088.9; ENSP00000305071.2; ENSG00000064490.15. [O14593-1]
DR   Ensembl; ENST00000407360.7; ENSP00000384572.3; ENSG00000064490.15. [O14593-1]
DR   Ensembl; ENST00000456252.7; ENSP00000409138.2; ENSG00000064490.15. [O14593-3]
DR   GeneID; 8625; -.
DR   KEGG; hsa:8625; -.
DR   MANE-Select; ENST00000303088.9; ENSP00000305071.2; NM_003721.4; NP_003712.1.
DR   UCSC; uc002nls.4; human. [O14593-1]
DR   AGR; HGNC:9987; -.
DR   ClinPGx; PA34357; -.
DR   CTD; 8625; -.
DR   DisGeNET; 8625; -.
DR   GeneCards; RFXANK; -.
DR   HGNC; HGNC:9987; RFXANK.
DR   HPA; ENSG00000064490; Low tissue specificity.
DR   MalaCards; RFXANK; -.
DR   MIM; 603200; gene.
DR   MIM; 620815; phenotype.
DR   OpenTargets; ENSG00000064490; -.
DR   Orphanet; 572; Immunodeficiency by defective expression of MHC class II.
DR   VEuPathDB; HostDB:ENSG00000064490; -.
DR   eggNOG; KOG0502; Eukaryota.
DR   GeneTree; ENSGT00940000160753; -.
DR   HOGENOM; CLU_000134_23_0_1; -.
DR   InParanoid; O14593; -.
DR   OMA; EQYMTAV; -.
DR   OrthoDB; 10251692at2759; -.
DR   PAN-GO; O14593; 2 GO annotations based on evolutionary models.
DR   PhylomeDB; O14593; -.
DR   PathwayCommons; O14593; -.
DR   SignaLink; O14593; -.
DR   SIGNOR; O14593; -.
DR   Agora; ENSG00000064490; -.
DR   BioGRID-ORCS; 8625; 26 hits in 1158 CRISPR screens.
DR   ChiTaRS; RFXANK; human.
DR   EvolutionaryTrace; O14593; -.
DR   GeneWiki; RFXANK; -.
DR   GenomeRNAi; 8625; -.
DR   Pharos; O14593; Tbio.
DR   PRO; PR:O14593; -.
DR   Proteomes; UP000005640; Chromosome 19.
DR   RNAct; O14593; protein.
DR   Bgee; ENSG00000064490; Expressed in lower esophagus mucosa and 189 other cell types or tissues.
DR   ExpressionAtlas; O14593; baseline and differential.
DR   GO; GO:0005829; C:cytosol; IDA:HPA.
DR   GO; GO:0045171; C:intercellular bridge; IDA:HPA.
DR   GO; GO:0005654; C:nucleoplasm; IDA:HPA.
DR   GO; GO:0005634; C:nucleus; IDA:ComplexPortal.
DR   GO; GO:0090575; C:RNA polymerase II transcription regulator complex; IPI:ARUK-UCL.
DR   GO; GO:0003677; F:DNA binding; IEA:UniProtKB-KW.
DR   GO; GO:0042826; F:histone deacetylase binding; IEA:Ensembl.
DR   GO; GO:0045348; P:positive regulation of MHC class II biosynthetic process; NAS:ComplexPortal.
DR   GO; GO:0045944; P:positive regulation of transcription by RNA polymerase II; IDA:GO_Central.
DR   GO; GO:0007265; P:Ras protein signal transduction; IEA:Ensembl.
DR   FunFam; 1.25.40.20:FF:000031; Ankyrin repeat, family A (RFXANK-like), 2; 1.
DR   Gene3D; 1.25.40.20; Ankyrin repeat-containing domain; 1.
DR   IDEAL; IID00427; -.
DR   InterPro; IPR002110; Ankyrin_rpt.
DR   InterPro; IPR036770; Ankyrin_rpt-contain_sf.
DR   InterPro; IPR017362; DNA-bd_RFXANK.
DR   PANTHER; PTHR24124; ANKYRIN REPEAT FAMILY A; 1.
DR   PANTHER; PTHR24124:SF4; DNA-BINDING PROTEIN RFXANK; 1.
DR   Pfam; PF00023; Ank; 1.
DR   Pfam; PF12796; Ank_2; 1.
DR   PIRSF; PIRSF038034; DNA-binding_RFXANK; 1.
DR   SMART; SM00248; ANK; 4.
DR   SUPFAM; SSF48403; Ankyrin repeat; 1.
DR   PROSITE; PS50297; ANK_REP_REGION; 1.
DR   PROSITE; PS50088; ANK_REPEAT; 3.
PE   1: Evidence at protein level;
KW   3D-structure; Activator; Alternative splicing; ANK repeat; Cytoplasm;
KW   Direct protein sequencing; Disease variant; DNA-binding; Nucleus;
KW   Proteomics identification; Reference proteome; Repeat; SCID; Transcription;
KW   Transcription regulation.
FT   CHAIN           1..260
FT                   /note="DNA-binding protein RFXANK"
FT                   /id="PRO_0000067049"
FT   REPEAT          89..118
FT                   /note="ANK 1"
FT   REPEAT          123..152
FT                   /note="ANK 2"
FT   REPEAT          156..185
FT                   /note="ANK 3"
FT   REPEAT          189..218
FT                   /note="ANK 4"
FT   REPEAT          222..251
FT                   /note="ANK 5"
FT   REGION          1..79
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        22..33
FT                   /note="Acidic residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        57..77
FT                   /note="Polar residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   VAR_SEQ         63
FT                   /note="Missing (in isoform 2)"
FT                   /evidence="ECO:0000303|PubMed:10072068"
FT                   /id="VSP_000283"
FT   VAR_SEQ         91..113
FT                   /note="SLSIHQLAAQGELDQLKEHLRKG -> C (in isoform 2 and
FT                   isoform 3)"
FT                   /evidence="ECO:0000303|PubMed:10072068,
FT                   ECO:0000303|PubMed:15489334"
FT                   /id="VSP_000284"
FT   VAR_SEQ         159..172
FT                   /note="Missing (in isoform 2)"
FT                   /evidence="ECO:0000303|PubMed:10072068"
FT                   /id="VSP_054618"
FT   VARIANT         48
FT                   /note="E -> D (in dbSNP:rs34282046)"
FT                   /id="VAR_048311"
FT   VARIANT         121
FT                   /note="D -> H (in MHC2D2; uncertain significance)"
FT                   /evidence="ECO:0000269|PubMed:37584719"
FT                   /id="VAR_089568"
FT   VARIANT         144
FT                   /note="L -> P (in MHC2D2; uncertain significance)"
FT                   /evidence="ECO:0000269|PubMed:30170160"
FT                   /id="VAR_089569"
FT   VARIANT         195
FT                   /note="L -> P (in MHC2D2; loss of expression;
FT                   dbSNP:rs751386365)"
FT                   /evidence="ECO:0000269|PubMed:10725724,
FT                   ECO:0000269|PubMed:22649097"
FT                   /id="VAR_009941"
FT   VARIANT         212..260
FT                   /note="Missing (in MHC2D2; uncertain significance)"
FT                   /evidence="ECO:0000269|PubMed:37584719"
FT                   /id="VAR_089570"
FT   VARIANT         251
FT                   /note="Q -> E (in dbSNP:rs1802498)"
FT                   /id="VAR_014472"
FT   MUTAGEN         121
FT                   /note="D->V: Loss of expression."
FT                   /evidence="ECO:0000269|PubMed:22649097"
FT   MUTAGEN         224
FT                   /note="Y->A: Loss of interaction with RFX5."
FT                   /evidence="ECO:0000269|PubMed:22649097"
FT   HELIX           94..99
FT                   /evidence="ECO:0007829|PDB:3V30"
FT   HELIX           103..110
FT                   /evidence="ECO:0007829|PDB:3V30"
FT   HELIX           115..118
FT                   /evidence="ECO:0007829|PDB:3V30"
FT   HELIX           127..133
FT                   /evidence="ECO:0007829|PDB:3V30"
FT   HELIX           137..146
FT                   /evidence="ECO:0007829|PDB:3V30"
FT   HELIX           160..166
FT                   /evidence="ECO:0007829|PDB:3V30"
FT   HELIX           170..177
FT                   /evidence="ECO:0007829|PDB:3V30"
FT   TURN            178..180
FT                   /evidence="ECO:0007829|PDB:3V30"
FT   HELIX           193..199
FT                   /evidence="ECO:0007829|PDB:3V30"
FT   HELIX           203..211
FT                   /evidence="ECO:0007829|PDB:3V30"
FT   HELIX           226..233
FT                   /evidence="ECO:0007829|PDB:3V30"
FT   HELIX           236..249
FT                   /evidence="ECO:0007829|PDB:3V30"
SQ   SEQUENCE   260 AA;  28102 MW;  6280B490F54816D2 CRC64;
     MELTQPAEDL IQTQQTPASE LGDPEDPGEE AADGSDTVVL SLFPCTPEPV NPEPDASVSS
     PQAGSSLKHS TTLTNRQRGN EVSALPATLD SLSIHQLAAQ GELDQLKEHL RKGDNLVNKP
     DERGFTPLIW ASAFGEIETV RFLLEWGADP HILAKERESA LSLASTGGYT DIVGLLLERD
     VDINIYDWNG GTPLLYAVRG NHVKCVEALL ARGADLTTEA DSGYTPMDLA VALGYRKVQQ
     VIENHILKLF QSNLVPADPE
//
